A preliminary evaluation of accelerator mass spectrometry in the biomedical field.
Kaye
B
B
Department of Drug Metabolism, Pfizer Central Research, Sandwich, Kent, UK.
Garner
R C
RC
Mauthe
R J
RJ
Freeman
S P
SP
Turteltaub
K W
KW
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics; D001698:Biomedical Engineering; D002247:Carbon Isotopes; D002250:Carbon Radioisotopes; D006801:Humans; D007189:Indans / Q000493:pharmacokinetics; D013058:Mass Spectrometry / Q000295:instrumentation*; D010315:Particle Accelerators; D010627:Phenethylamines / Q000493:pharmacokinetics; D011422:Propionates / Q000493:pharmacokinetics; D011480:Protease Inhibitors / Q000493:pharmacokinetics; D051381:Rats; D013449:Sulfonamides / Q000493:pharmacokinetics
D000889:Anti-Arrhythmia Agents; D002247:Carbon Isotopes; D002250:Carbon Radioisotopes; D007189:Indans; D010627:Phenethylamines; D011422:Propionates; D011480:Protease Inhibitors; D013449:Sulfonamides; C062766:candoxatril; C063533:dofetilide